Medication nonadherence secondary to drug-induced memory loss
- PMID: 20211824
- DOI: 10.4140/TCP.n.2010.117
Medication nonadherence secondary to drug-induced memory loss
Abstract
Overactive bladder (OAB) is a common condition in the elderly. Treatments for OAB include nonpharmacological or behavioral therapy, pharmacological therapy, and surgical therapy. Antimuscarinic agents are the current pharmacological treatment for OAB and are known to cause memory impairment. A 66-year-old female presented with memory loss secondary to the administration of oxybutynin, which resulted in medication nonadherence. Upon review of her medications, the pharmacist recommended discontinuing the oxybutynin because of the anticholinergic effects on cognition. At a three-week follow-up visit, the patient reported an improvement in memory and medication adherence. Pharmacists can play a vital role in recognizing drug-induced side effects and educating patients in an effort to improve medication adherence.
Similar articles
-
Patient-reported reasons for discontinuing overactive bladder medication.BJU Int. 2010 May;105(9):1276-82. doi: 10.1111/j.1464-410X.2009.09036.x. Epub 2009 Nov 12. BJU Int. 2010. PMID: 19912188
-
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.BJU Int. 2007 Apr;99(4):836-44. doi: 10.1111/j.1464-410X.2006.06658.x. Epub 2006 Dec 20. BJU Int. 2007. PMID: 17187655 Clinical Trial.
-
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.Eur Urol. 2006 Aug;50(2):317-26. doi: 10.1016/j.eururo.2006.03.057. Epub 2006 Apr 19. Eur Urol. 2006. PMID: 16687205 Clinical Trial.
-
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682. Expert Opin Pharmacother. 2009. PMID: 19954278 Review.
-
Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.Curr Med Res Opin. 2007 Aug;23(8):1903-12. doi: 10.1185/030079907X210598. Curr Med Res Opin. 2007. PMID: 17610806 Review.
Cited by
-
Cognitive Function before and during Treatment with Selective Serotonin Reuptake Inhibitors in Patients with Depression or Obsessive-Compulsive Disorder.Psychiatry J. 2016;2016:5480391. doi: 10.1155/2016/5480391. Epub 2016 Aug 15. Psychiatry J. 2016. PMID: 27597949 Free PMC article.
-
Overactive bladder: the importance of tailoring treatment to the individual patient.J Multidiscip Healthc. 2011;4:233-7. doi: 10.2147/JMDH.S21401. Epub 2011 Jul 22. J Multidiscip Healthc. 2011. PMID: 21847345 Free PMC article.
-
Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. Drugs Aging. 2012. PMID: 22390261 Review.
-
Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations.Drugs Aging. 2015 Jul;32(7):559-67. doi: 10.1007/s40266-015-0281-x. Drugs Aging. 2015. PMID: 26169438 Review.
-
Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.Int Urogynecol J. 2011 Aug;22(8):907-17. doi: 10.1007/s00192-011-1411-6. Epub 2011 Apr 6. Int Urogynecol J. 2011. PMID: 21468739 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical